A052

A052: sourced facts only. name: "Evaluation through enzyme-linked immunosorbent assay, flow cytometry, and bio-layer interferometry revealed that A052 binds with a significantly higher affinity (KD = 77.2 pM) compared to the anti-B7-H3 IgG antibody, hBRCA84D, currently in clinical trials (KD = 8.13 nM)." [PMID:40684715]; target: "Evaluation through enzyme-linked immunosorbent assay, flow cytometry, and bio-layer interferometry revealed that A052 binds with a significantly higher affinity (KD = 77.2 pM) compared to the anti-B7-H3 IgG antibody, hBRCA84D, currently in clinical trials (KD = 8.13 nM)." [PMID:40684715]; developer: "Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China; Changzhou Key Laboratory of Molecular Imaging, 213003, Jiangsu, China." [PMID:40684715]; modality: "In this study, a novel fusion antibody, A052, was developed, integrating the variable domain of a nanobody heavy chain (VHH) and the Fc domain of IgG1." [PMID:40684715]; stage: "To compare the in vivo tumor accumulation properties, both A052 and hBRCA84D were labeled with Cy5 and assessed in a PANC-1 xenograft model using infrared imaging." [PMID:40684715]